Challenging obesity, diabetes, and addiction: the potential of lorcaserin extended release
Ryan T Hurt,1–4 Manpreet S Mundi,3 Jon O Ebbert5 1Division of General Internal Medicine, Mayo Clinic, Rochester, MN, USA; 2Division of Gastroenterology and Hepatology, Mayo Clinic, Rochester, MN, USA; 3Division of Endocrinology, Diabetes, Metabolism and Nutrition, Mayo Clinic, Rochester, M...
Guardado en:
Autores principales: | Hurt RT, Mundi MS, Ebbert JO |
---|---|
Formato: | article |
Lenguaje: | EN |
Publicado: |
Dove Medical Press
2018
|
Materias: | |
Acceso en línea: | https://doaj.org/article/30bc9e7e93e84bcfac4840001f22ecfc |
Etiquetas: |
Agregar Etiqueta
Sin Etiquetas, Sea el primero en etiquetar este registro!
|
Ejemplares similares
-
Converging Relationships of Obesity and Hyperuricemia with Special Reference to Metabolic Disorders and Plausible Therapeutic Implications
por: Gong M, et al.
Publicado: (2020) -
Lorcaserin Inhibit Glucose-Stimulated Insulin Secretion and Calcium Influx in Murine Pancreatic Islets
por: Muhan Jing, et al.
Publicado: (2021) -
Lorcaserin for weight management
por: Taylor JR, et al.
Publicado: (2013) -
Off-label drugs for weight management
por: Hendricks EJ
Publicado: (2017) -
Management of obesity and cardiometabolic risk – role of phentermine/extended release topiramate
por: Sweeting AN, et al.
Publicado: (2014)